SCHEMBL1594980

SCHEMBL1594980

CN(C)C(=O)c1ccc(-c2cc(-c3ccccc3)nn2-c2ccc([N+](=O)[O-])cc2)s1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.45
LMNA P02545 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 3/20 0.42
RARG P13631 1/20 0.41
RXRA P19793 1/20 0.41
PHGDH O43175 1/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15905607 0.87 CYP2C9 (0.49) NQO2LMNANPC1RAB9AALDH1A1
SCHEMBL12706090 0.86 NQO2 (0.45) NQO2NPC1RAB9AALDH1A1PHGDH
SCHEMBL1593629 0.83 NPC1 (0.52) NPC1RAB9AALDH1A1RARGRXRA
SCHEMBL1594352 0.82 RAB9A (0.64) LMNANPC1RAB9AALDH1A1KDM4E
SCHEMBL1596407 0.78 RAB9A (0.62) NPC1RAB9AALDH1A1PHGDHSMN1; SMN2
SCHEMBL3447083 0.77 CYP2C9 (0.55) NQO2LMNANPC1RAB9AALDH1A1
SCHEMBL1593870 0.77 ALDH1A1 (0.53) NPC1RAB9AALDH1A1RXRASMN1; SMN2
SCHEMBL1594109 0.76 NPC1 (0.50) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL1593772 0.75 NPC1 (0.47) NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL1593680 0.74 RAB9A (0.70) NPC1RAB9AALDH1A1RXRAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791137-B2 Therapeutic compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2014-07-29 US disclosed
US-8791137-B2 Therapeutic compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2014-07-29 US disclosed
EP-1989185-B1 THERAPEUTIC COMPOUNDS HELICON THERAPEUTICS INC (US) 2013-05-22 EP disclosed
US-8399487-B2 Pyrazole compounds and uses thereof DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-03-19 US disclosed
US-8399487-B2 Pyrazole compounds and uses thereof DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-03-19 US disclosed
US-20110160248-A1 PYRAZOLE COMPOUNDS AND USES THEREOF DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-06-30 US disclosed
US-20110160248-A1 PYRAZOLE COMPOUNDS AND USES THEREOF DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-06-30 US disclosed
US-7919626-B2 Pyrazole compounds and uses thereof HELICON THERAPEUTICS, INC. (US) 2011-04-05 US disclosed
US-7919626-B2 Pyrazole compounds and uses thereof HELICON THERAPEUTICS, INC. (US) 2011-04-05 US disclosed
US-20100317648-A1 THERAPEUTIC COMPOUNDS DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2010-12-16 US disclosed
US-20100317648-A1 THERAPEUTIC COMPOUNDS DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2010-12-16 US disclosed
US-20070203154-A1 Therapeutic Compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2007-08-30 US disclosed
US-20070203154-A1 Therapeutic Compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317648-A1 THERAPEUTIC COMPOUNDS MAOB, MAOA, HTR1B NQO2 262/4885LMNA 3022/4885NPC1 1407/4885
US-20110160248-A1 PYRAZOLE COMPOUNDS AND USES THEREOF MAOB, MAOA, HTR1B NQO2 531/4885LMNA 3759/4885NPC1 3317/4885
US-20070203154-A1 Therapeutic Compounds MAOB, MAOA, HTR1B NQO2 262/4885LMNA 3022/4885NPC1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.